US FDA grants Breakthrough Therapy Designation for Takeda’s Pevonedistat EP News Bureau Jul 31, 2020 The investigational drug is for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS)
Key pipeline advancements to propel myelodysplastic syndromes market to $2.4 bn by 2028: GlobalData EP News Bureau Jun 28, 2020 Despite the recent surge of development within the MDS space, KOLs argue that the level of unmet need remained dire.
